Cargando…

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry

BACKGROUND & AIMS: No multi‐national prospective study of drug‐induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short‐term outcomes of the cases and controls is reported. METHODS: Patients with suspected DILI were pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Björnsson, Einar S., Stephens, Camilla, Atallah, Edmond, Robles‐Diaz, Mercedes, Alvarez‐Alvarez, Ismael, Gerbes, Alexander, Weber, Sabine, Stirnimann, Guido, Kullak‐Ublick, Gerd, Cortez‐Pinto, Helena, Grove, Jane I., Lucena, M. Isabel, Andrade, Raul J., Aithal, Guruprasad P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Metabolic & Toxic Liver Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614006/ https://www.ncbi.nlm.nih.gov/pubmed/35899490 http://dx.doi.org/10.1111/liv.15378

Ejemplares similares

Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
por: Bessone, Fernando, et al.
Publicado: (2022)

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
por: Brennan, Paul N, et al.
Publicado: (2021)

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
por: Calleja, José L., et al.
Publicado: (2022)

Biomarkers in DILI: One More Step Forward
por: Robles-Díaz, Mercedes, et al.
Publicado: (2016)

NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction
por: Verwer, Bart J., et al.
Publicado: (2020)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma
por: Nardo, Alexander D., et al.
Publicado: (2020)

Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease
por: Sangineto, Moris, et al.
Publicado: (2020)

The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease
por: Simons, Nynke, et al.
Publicado: (2020)

Absence of Bsep/Abcb11 attenuates MCD diet‐induced hepatic steatosis but aggravates inflammation in mice
por: Fuchs, Claudia D., et al.
Publicado: (2020)

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
por: Yen, Fu‐Shun, et al.
Publicado: (2020)

Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population
por: Damba, Turtushikh, et al.
Publicado: (2020)

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease
por: Eder, Sebastian K., et al.
Publicado: (2020)

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids
por: de Mello, Vanessa D., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Interaction between CHOP and FoxO6 promotes hepatic lipid accumulation
por: Kim, Dae Hyun, et al.
Publicado: (2020)

Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review
por: Draijer, Laura G., et al.
Publicado: (2021)

Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2021)

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
por: Colosimo, Santo, et al.
Publicado: (2021)

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
por: George, Elena S., et al.
Publicado: (2022)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
por: Mendoza, Yuly P., et al.
Publicado: (2021)

Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008‐2019
por: Sugiyama, Aya, et al.
Publicado: (2021)

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
por: Björkström, Karl, et al.
Publicado: (2022)

Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
por: Balkhed, Wile, et al.
Publicado: (2022)

Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
por: Villeret, François, et al.
Publicado: (2022)

Inhibition of polyploidization in Pten‐deficient livers reduces steatosis
por: Moreno, Eva, et al.
Publicado: (2022)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Drug-induced liver injury: recent advances in diagnosis and risk assessment
por: Kullak-Ublick, Gerd A, et al.
Publicado: (2017)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes
por: Schaffner, Carlos A, et al.
Publicado: (2015)

Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study
por: Grove, Jane I., et al.
Publicado: (2023)

Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury
por: Gai, Zhibo, et al.
Publicado: (2023)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012)

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans
por: Ravindra, Kodihalli C., et al.
Publicado: (2023)

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review
por: Niu, Hao, et al.
Publicado: (2022)

Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review
por: Björnsson, Einar S., et al.
Publicado: (2022)

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
por: Regev, Arie, et al.
Publicado: (2014)

Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH)
por: Gordon, Victoria Mary, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hkrt133re5virep3as8jd3ev5b